Israel has registered eight cases of a coronavirus variant first identified in India and believes that the Pfizer/BioNTech vaccine is at least partially effective against it, an Israeli health official said. “The impression is that the Pfizer vaccine has efficacy against it, albeit a reduced efficacy,” the ministry’s director-general, Hezi Levy, told Kan public radio, saying the number of cases of the variant in Israel now stood at eight.
People in the UK have been infected with Covid-19 more than once thanks to catching different variants of the coronavirus. Dr Susan Hopkins, chief medical adviser for NHS Test and Trace, said there had been cases where people had become reinfected by different strains of the coronavirus. “We have seen some people who have had their first dose of vaccine who have had the South African variant and the variant that arose in Kent,” she told BBC’s the Andrew Marr show. “You can see that they’re not as good against the South African variant as they are against our own (variant) B117 at preventing infection and transmission.”
Prof Paul Hunter, professor in medicine at the University of East Anglia, told the Guardian that the arrival of the India variant was potentially worrying. He said: “These two escape mutations working together could be a lot more problematic than the South African and Brazilian variants which have only got one escape mutation. “It might be even less controlled by vaccine than the Brazilian and South African variants.”
The variant featured two “escape mutations” – E484Q and L452R – that “are causing people to be concerned. “There’s laboratory evidence that both of these are escape mutations. Basically, applying what we know about other human coronaviruses would suggest that this is going to be even less controlled by vaccine. But we don’t know that for certain at the moment”
About 5,800 Americans who have been vaccinated against coronavirus have become infected anyway, the U.S. Centers for Disease Control and Prevention tells CNN. Some became seriously ill and 74 people died, the CDC said. It said 396 — 7% — of those who got infected after they were vaccinated required hospitalization.
It’s the first indication from CDC of how effective the vaccine is in real life — and the first indication the vaccines do not protect completely against severe disease and death.
Australian Federal health authorities are investigating the death of a 48-year-old New South Wales woman who developed blood clots after receiving a COVID-19 vaccine. If it is confirmed the woman contracted blood clots linked to a COVID-19 vaccine, it would be the third such case in Australia since the rollout began.
As of Thursday (April 8), 170 people in Louisiana were classified as having a “breakthrough” vaccine COVID case – testing positive for coronavirus after being fully vaccinated. A week earlier, the state reported 126 cases. The health department released new data Thursday during a news conference after WBRZ made repeated requests for information.
Nearly 300 Rhode Islanders have tested positive for COVID-19 after being vaccinated against the virus — a total that state public-health officials consider a positive sign of the vaccines’ effectiveness. Three of the state’s 290 post-vaccination positive cases died and 20 were hospitalized, the state Department of Health said Tuesday.
The 290 “breakthrough” infections, as post-vaccine cases are known, came out of 212,060 people who received their final shot 14 days ago, representing about 0.13% of that group.
Denmark has received the first claim for compensation for a death caused by a special type of blood clot, which the authorities link with the Astrazeneca vaccine. The patient compensation scheme has received a total of 29 compensation applications from citizens who have received the Astrazeneca vaccine. A further eight cases concern the Pfizer vaccine. There are no claims for Moderna.
This is stated by Patienterstatningen, which handles cases of compensation for citizens who are affected by serious side effects from e.g. medicines.
The Mississippi State Department of Health is reporting 78 breakthrough cases of COVID-19. Of those 78 breakthrough cases, one individual died of COVID-19.
“That’s one of the things that we’re following, is to look at who is being impacted with breakthrough COVID after they’ve been fully vaccinated,” said state epidemiologist Dr. Paul Byers.
State health leaders said there are 635,000 fully vaccinated Mississippians and the number of breakthrough cases is comparatively low. They said that’s proof the vaccines are working.
Compared to immunocompetent controls, a three-fold reduction in anti-S IgG titers (P=0.009) and SARS-CoV-2 neutralization (p<0.0001) were observed in CID patients. B cell depletion and glucocorticoids exerted the strongest effect with a 36- and 10-fold reduction in humoral responses, respectively (p<0.0001). Janus kinase inhibitors and antimetabolites, including methotrexate, also blunted antibody titers in multivariate regression analysis (P<0.0001, P=0.0023, respectively). Other targeted therapies, such as TNF inhibitors, IL-12/23 inhibitors, and integrin inhibitors, had only modest impacts on antibody formation and neutralization.
Conclusions CID patients treated with immunosuppressive therapies exhibit impaired SARS-CoV-2 vaccine-induced immunity, with glucocorticoids and B cell depletion therapy more severely impeding optimal responses.
More than 580 Illinoisans have tested positive for COVID-19 despite being fully vaccinated. The Illinois Department of Public Health reported that of the about 2.5 million people in Illinois who have been fully vaccinated, as of data compiled Wednesday, 581 tested positive for COVID-19 after getting their final vaccine dose.
New research from the U.S. Centers for Disease Control and Prevention suggests that people who receive Moderna’s COVID-19 vaccine might experience more side effects than those who get Pfizer/BioNTech’s vaccine. The agency’s findings come from a study published in the online journal JAMA. The data revealed that 75% of Moderna recipients reported side effects after getting one dose of the COVID-19 vaccine compared to 65% of the Pfizer/BioNTech recipients. Side effects included pain at the injection site, fatigue and headaches.
An Israeli study released today in the country has shown that the South African variant of the coronavirus is more resistant than the British variant against the vaccine Pfizer, although it did not specify the degree of resistance.
The research was based on a sample of about 800 people and found that the percentage of cases of the South African strain compared to the British was significantly higher among people who had received both doses of the vaccine compared to those who had only been inoculated with one.
The study, carried out by researchers from the main Israeli health company, insurance Clalit , together with Tel Aviv University , identified that among infected patients 14 days after receiving the first dose of the vaccine, less than 0.5% had contracted the South African strain of coronavirus. This figure was almost identical when analyzing a control group, made up of the same number of patients, of similar ages and who had not received the vaccine .
What was striking was that among the people who had been infected with coronavirus within two weeks of receiving the second dose of the vaccine, the percentage of patients carrying the South African strain was 5.4%, while in the control group of unvaccinated people the figure was 0.7%.